Quarterly report pursuant to Section 13 or 15(d)

Business (Details)

v3.20.1
Business (Details)
 1 Months Ended 3 Months Ended
Mar. 17, 2020
USD ($)
$ / shares
shares
Feb. 06, 2020
USD ($)
$ / shares
shares
Feb. 03, 2020
USD ($)
shares
Sep. 04, 2019
USD ($)
$ / shares
shares
Mar. 08, 2019
$ / shares
shares
Apr. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
$ / shares
shares
Feb. 29, 2020
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
shares
Mar. 31, 2020
USD ($)
product
$ / shares
Dec. 31, 2019
USD ($)
shares
Mar. 31, 2019
USD ($)
Nov. 01, 2019
shares
Subsequent Event [Line Items]                          
Sale of stock (in shares) | shares         363,637                
Purchase price (in dollars per share) | $ / shares         $ 5.50                
Net loss                   $ (21,117,106)   $ (7,454,048)  
Net cash used in operating activities                   (5,740,074)   (3,121,552)  
Accumulated deficit             $ (135,407,723)   $ (114,290,617) (135,407,723) $ (114,290,617)    
Cash and cash equivalents             $ 5,659,384   3,609,438 $ 5,659,384 3,609,438 $ 16,121,388  
Neurological Clinical And Preclinical Stage Compounds                          
Subsequent Event [Line Items]                          
Number of products in development | product                   3      
Registered Direct Offering                          
Subsequent Event [Line Items]                          
Sale of stock (in shares) | shares   1,306,282           1,306,282          
Purchase price (in dollars per share) | $ / shares   $ 3.98           $ 3.98          
Armistice Purchase Agreement                          
Subsequent Event [Line Items]                          
Sale of stock (in shares) | shares 1,951,219     1,200,000     1,951,219            
Purchase price (in dollars per share) | $ / shares $ 2.05     $ 3.132     $ 2.05     $ 2.05      
Net proceeds $ 3,900,000     $ 3,700,000     $ 3,900,000            
Aevi                          
Subsequent Event [Line Items]                          
Loan forgiven     $ 4,100,000           4,100,000        
Armistice | Registered Direct Offering | Common stock                          
Subsequent Event [Line Items]                          
Sale of stock (in shares) | shares   1,256,282           1,256,282          
Net proceeds   $ 5,000,000           $ 5,000,000          
Pediatric Portfolio                          
Subsequent Event [Line Items]                          
Proceeds from sale of assets                     4,500,000    
Assumption of debt on sale of assets                 15,100,000   15,100,000    
Gain on disposal                     8,000,000    
Pediatric Portfolio | AYTU                          
Subsequent Event [Line Items]                          
Liabilities assumed by buyer                 $ 11,000,000   $ 11,000,000    
Aevi                          
Subsequent Event [Line Items]                          
Consideration transferred, shares issued     $ 15,500,000                    
Shares issued (in shares) | shares     3,900,000                    
Contingent consideration     $ 6,500,000                    
AYTU | Convertible Preferred Stock                          
Subsequent Event [Line Items]                          
Investment (in shares) | shares                 9,800,000   9,800,000   9,800,000
Subsequent Event | AYTU | Common stock                          
Subsequent Event [Line Items]                          
Net proceeds           $ 12,800,000